Amalgamated Bank Sells 253 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Amalgamated Bank trimmed its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,868 shares of the medical research company’s stock after selling 253 shares during the quarter. Amalgamated Bank’s holdings in Charles River Laboratories International were worth $1,822,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Versant Capital Management Inc lifted its stake in Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. increased its holdings in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares during the period. Assetmark Inc. raised its position in shares of Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares in the last quarter. ORG Wealth Partners LLC purchased a new stake in shares of Charles River Laboratories International in the fourth quarter worth $56,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in Charles River Laboratories International during the third quarter valued at $59,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the topic of several recent analyst reports. UBS Group reaffirmed a “neutral” rating and issued a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Robert W. Baird lowered their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Evercore ISI increased their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus price target of $195.71.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $165.01 on Monday. The firm has a fifty day simple moving average of $170.94 and a two-hundred day simple moving average of $186.85. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $275.00. The company has a market capitalization of $8.44 billion, a PE ratio of 1,100.04, a P/E/G ratio of 4.54 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same quarter in the previous year, the company posted $2.46 EPS. Charles River Laboratories International’s revenue for the quarter was down 1.1% on a year-over-year basis. Research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other news, CEO James C. Foster acquired 6,075 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were purchased at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares of the company’s stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Birgit Girshick bought 1,514 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were purchased at an average price of $164.63 per share, with a total value of $249,249.82. Following the completion of the acquisition, the chief operating officer now owns 55,058 shares of the company’s stock, valued at $9,064,198.54. This trade represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).